Windlas Biotech Limited, a leading Indian pharmaceutical CDMO, announced today that its new injectable manufacturing facility has received Good Manufacturing Practices (GMP) certification from Uttarakhand’s Food Safety & Drugs Administration Authority. The certification, following a December 2024 inspection, confirms the facility’s compliance with WHO TRS Guidelines.

The shares of Windlas Biotech Limited were trading at ₹1,007.10 down by ₹8.95 or 0.88 per cent on the NSE today at 2.20 pm.

The newly certified facility, equipped with automated systems and quality control mechanisms, represents the company’s fifth GMP-compliant manufacturing plant. Managing Director Hitesh Windlass stated that the certification would enable the company to expand its product portfolio in the CDMO space and meet growing demand for injectable pharmaceutical products in domestic and global markets.

• Also read: Liquidity management may take priority over rate cuts in February MPC

Windlas Biotech, ranked among India’s top five pharmaceutical formulations CDMO players, has over two decades of experience manufacturing solid and liquid pharmaceutical dosage forms. The company specialises in high potency and controlled substances manufacturing, while also marketing branded trade generics and institutional products across India.

The GMP certification marks a significant expansion of Windlas Biotech’s manufacturing capabilities, particularly in sterile injectable formulations. The company’s new facility features eco-friendly processes and advanced infrastructure designed for efficient production of sterile injectables, positioning it to serve a wider range of therapeutic areas.